RhumbLine Advisers
SLS icon

RhumbLine Advisers’s SELLAS Life Sciences SLS Stock Holding History

RhumbLine Advisers’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.4M Buy
230,402
+36,204
+19% +$250K ﹤0.01% 1656
2026
Q1 		$821K Buy
194,198
+64,889
+50% +$290K ﹤0.01% 2301
2025
Q4 		$487K Sell
129,309
-7,330
-5% -$14.2K ﹤0.01% 2681
2025
Q3 		$220K Buy
136,639
+850
+0.6% +$1.51K ﹤0.01% 3173
2025
Q2 		$297K Buy
+135,789
New +$208K ﹤0.01% 2990

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

RhumbLine Advisers's SLS Position: Q2 2026 in Review

RhumbLine Advisers increased its SELLAS Life Sciences (SLS) stake by 19% in Q2 2026, buying an estimated $250K and bringing the position to 230,402 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1656.

RhumbLine Advisers first reported a position in SLS in Q2 2025 and has held it in 5 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • RhumbLine Advisers held 230,402 shares of SELLAS Life Sciences worth $3.4M as of Q2 2026.
  • RhumbLine Advisers bought 36,204 SELLAS Life Sciences shares in Q2 2026, an estimated $250K.
  • SELLAS Life Sciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1656 holding.
  • RhumbLine Advisers first reported a position in SELLAS Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.